Physician profile
Jamsheed Akhavan
NPI 1073661807
$1,230.20
in general payments reported to CMS, 2019-2025
15 companies · $250 in 2025
The $250 reported for 2025 was more than what 80% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $191 · 2021: $221 · 2022: $52.74 · 2023: $51.17 · 2024: $13.82 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $231.11 | 2019-2020 | |
| Amgen INC. | $152.63 | 2019-2025 | Evenity |
| Lilly USA, LLC | $139.85 | 2019-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $129.84 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.94 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $93.89 | 2019-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $88.80 | 2019-2022 | |
| Novo Nordisk INC | $72.87 | 2021-2025 | Wegovy, Saxenda |
| Bayer Healthcare Pharmaceuticals INC. | $70.86 | 2023-2025 | |
| Pfizer INC. | $43.13 | 2020-2022 | |
| Madrigal Pharmaceuticals | $23.48 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $17.61 | 2021 | |
| Phadia US INC. | $17.09 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.53 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamsheed Akhavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.